There has been a great deal of concern around the deployment of vaccines across our country. The pandemic continues to take a toll on individuals and local businesses, and I share with you the anticipation for the day that we achieve enough herd immunity to move beyond our current lockdowns and restrictions.
The recent interruptions of our vaccine supply have been disappointing, but this week, Minister Anand indicated that from February 15th onwards there will be a steep increase in our shipments. The Prime Minister reiterated this positive development last night.
We remain on track to reach our vaccine delivery targets for the first quarter. In addition, Health Canada is in the end-stages of reviewing vaccine candidates from Novavax, AstraZeneca and Johnson & Johnson. Minister Anand has been in touch with both AstraZeneca and J&J representatives to ensure immediate delivery of those vaccines, as soon as there is regulatory approval.
When this pandemic was first declared, Canada was at a disadvantage due to the decades-long trend of biomanufacturing disinvestment by successive governments. Twelve days into the pandemic, our government announced funding and support for strategic investments in domestic manufacturing companies (including Medicago which is in stage 3 of its clinical trials, Variation Biotechnologies, and Precision Nanosystems). Our government also requested seven of the firms providing vaccines to Canada to consider manufacturing domestically; however, they deemed our facilities under-equipped for such a venture.
In that context, Canada was the first country in the world to sign a contract with Moderna and the fourth to sign a contract with Pfizer. Risks in supply chains, unpredictability, and increased demand for production were to be anticipated, but that doesn't lessen our disappointment in the delays we have seen.
Last week we announced a partnership with Novavax to pursue domestic production of their COVID-19 vaccine at the National Research Council's Biologics Manufacturing Centre, in which we had already invested in upgrades of over $100M. We also committed to purchasing 52 million doses of the Novavax candidate COVID-19 vaccine, with an option for an additional 24 million doses. COVID-19 and its variants will not be the last time we are forced to create vaccines, so an investment of $46M has also been made in the University of Saskatchewan's Vaccine and Infectious Disease Organization, which will eventually be able to produce 40 million doses annually.
|